

Access Scientific, LLC unveils partnership with Smiths Medical to sell Access' POWERWAND™ product lines and completion of a \$20M capital raise.

Healthcare providers to benefit from significantly improved access to the clinically superior POWERWAND, shown to reduce CLABSIs and the overall cost of care

San Diego, CA (insert date) – Access Scientific, LLC, a leading provider of extended dwell and midline catheters, announced the signing of a sales agreement with Smiths Medical to sell the POWERWAND™ product line in the United States. The POWERWAND product line helps Smiths Medical extend their vascular access product portfolio into the extended dwell and midline catheter categories – the fastest growing devices within the vascular access device segment (valued at \$1.6B¹).

The POWERWAND is viewed as a clinically superior product, supported by seven (7) peer reviewed papers and nine (9) scientific posters. These studies have documented over 35,000 catheter-days with ZERO bloodstream infections and have shown the POWERWAND may contribute to reduced overall CLABSIs and generate significant cost savings[‡]. The most recent peer reviewed publication, released this past January in a Dove Medical Press journal, helps explain why the POWERWAND may have achieved some of its unparalleled results. Comprised of ChronoFlex C® with BloGUARD™, it is the only non-coated and non-impregnated catheter in the market that has been shown to inhibit bacterial attachment (in vitro) as compared with the standard polyurethane used in most intravenous catheters². With growing concern around patient risk and cost burden associated with catheter-related bloodstream infections, the POWERWAND offers superior value to healthcare providers looking to offer quality care at lower costs.

“With the growing emphasis on quality of care and the increased financial penalties associated with hospital acquired conditions (HACs), hospitals are seeking products that help them achieve better clinical outcomes and reduced costs. These outcomes include reduced catheter-related bloodstream infection rates, improved patient satisfaction and lower overall costs — this is why demand for our POWERWAND catheter products is at an all time high. Partnering with Smiths Medical allows us to reach a broader market, ultimately helping improve the lives of more patients,” said Jeff Goble, Access Scientific’s CEO.

To expand marketing and sales of POWERWAND in association with the Smiths Medical relationship, Access Scientific has secured \$20M in additional capital funding from existing shareholders and a new long term credit facility. This new funding allows Access to further invest in product development, increased production capacity and expanded sales & marketing efforts.

About Access Scientific, LLC.

Access Scientific LLC is a broad-spectrum vascular access/infection prevention company. The POWERWAND midlines and extended-dwell catheters set a new standard for safety and ease of

use. Learn more about the POWERWAND family of products and their supporting science at www.accessscientific.com.

1. 2019 iData Market Research
2. Proven in vitro to significantly ($p=0.0133$) inhibit bacterial attachment and biofilm formation[†] as compared with a commonly used polyurethane catheter
3. Pathak R, Bierman S, d'Arnaud P. Inhibition of bacterial attachment and biofilm formation by a novel intravenous catheter material using an in vitro percutaneous catheter insertion model. Medical Devices: Evidence and Research. 2018;11:1-6. <https://doi.org/10.2147/MDER.S183409>.

[†] Based on laboratory test results which may not be indicative of clinical results. Data on file and refer to publication³. Preclinical in-vitro evaluations do not necessarily predict clinical performance with respect to catheter-related bloodstream infection.

[‡] Data on File.

POWERWAND™ and BioGUARD™ (Access Scientific LLC, San Diego, CA) - a registered trademark of Access Scientific LLC

ChronoFlex C® is a registered trademark of Advance Source Biomaterials Corp